Joseph Michael Fitzgerald - Jan 1, 2023 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
EVP & Group Pres, Cardiology
Signature
/s/ Susan Thompson, Attorney-in-Fact
Stock symbol
BSX
Transactions as of
Jan 1, 2023
Transactions value $
-$308,066
Form type
4
Date filed
1/3/2023, 03:26 PM
Previous filing
Dec 14, 2022
Next filing
Feb 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $0 +13.1K +6.06% $0.00 230K Jan 1, 2023 Direct F1
transaction BSX Common Stock Tax liability -$308K -6.66K -2.89% $46.27 223K Jan 1, 2023 Direct
holding BSX Common Stock 68.1K Jan 1, 2023 By 401(k) F2
holding BSX Common Stock 7.43K Jan 1, 2023 By Children F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Performance Share Units Options Exercise $0 -13.1K -100% $0.00* 0 Jan 1, 2023 Common Stock 13.1K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022.
F2 Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
F3 The reporting person disclaims beneficial ownership of the shares held by his children, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or for any other purpose.
F4 Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.